Innovative
Biopharmaceutical Company

Based on Mitochondria

Who We Are

PAEAN Biotechnology, a pioneer in mitochondria-based therapeutics, is the first company to develop mitochondria as biopharmaceutical agents to treat diseases. Using our first-in-class proprietary technology of isolating, storing, and modifying mitochondria, we developed a revolutionary treatment to address rare diseases and cancer.

Mission

PAEAN Biotechnology strives to develop revolutionary first-in-class medicinal products through a proprietary platform based on the unique characteristics of mitochondria. We have developed three platforms of MitoTransfer.

Mitochondrial Therapeutics (MitoTherapy) Products

Read more >>

Mitochondrial Cell Therapy Products

Read more >>

Modified MitoTherapy Products

Read more >>

Milestone

Research Collaboration

Seoul National University Hospital




2018 - Now

Pre-series A Funding

Korea Investment Partners




KRW 1.5 B

Jun 2018

Series A Funding

Korea Investment Partners, Hana Ventures, Timefolio



KRW 6 B

Jun 2019

Bridge Funding

Korea Investment Partners, Hana Ventures, Timefolio



KRW 4.5 B

Jan 2021

Mitochondria GMP Facility





Jung-gu, Seoul

Jun 2021

PN-101 MFDS IND Approval

World-first allogeneic mitochondria as therapeutic agent



Jun 2021

Research Collaboration

MOU with Soonchunhyang University Medical Center and SIMS



Sep 2021 - Now

Series B Funding

Daol Investment, Hana Ventures, Timefolio, IMM Investment


KRW 7 B

Sep 2022

Research Collaboration

MOU with YiPSCELL





Dec 2022 - Now

Press Highlights

입셀·파이안바이오, 미토콘드리아 재생의료 치료제 개발 협약

Source: https://www.hankyung.com/it/article/202212083036i

Read more >>
Dec 08, 2022

파이안바이오 "미토콘드리아 치료제, 해외 제약사 2곳과 공동연구"

Source: https://www.hankyung.com/it/article/202207122116i

Read more >>
Jul 12, 2022

미토콘드리아 치료제 세계 첫 임상… 면역세포 치료-항암제까지

Source: https://www.donga.com/news/It/article/all/20220423/113035474/1?ref=main

Read more >>
Apr 23, 2022